skip to main content

H.R. 4982 (114th): Examining Opioid Treatment Infrastructure Act of 2016

The text of the bill below is as of May 10, 2016 (Reported by House Committee).


IB

Union Calendar No. 434

114th CONGRESS

2d Session

H. R. 4982

[Report No. 114–560]

IN THE HOUSE OF REPRESENTATIVES

April 18, 2016

(for himself and Mr. Pallone) introduced the following bill; which was referred to the Committee on Energy and Commerce

May 10, 2016

Additional sponsors: Ms. Herrera Beutler, Mr. Rokita, Mr. Kilmer, and Mr. Turner

May 10, 2016

Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed

Strike out all after the enacting clause and insert the part printed in italic

For text of introduced bill, see copy of bill as introduced on April 18, 2016


A BILL

To direct the Comptroller General of the United States to evaluate and report on the in-patient and outpatient treatment capacity, availability, and needs of the United States.


1.

Short title

This Act may be cited as the Examining Opioid Treatment Infrastructure Act of 2016.

2.

Study on treatment infrastructure

Not later than 24 months after the date of enactment of this Act, the Comptroller General of the United States shall initiate an evaluation, and submit to Congress a report, of the inpatient and outpatient treatment capacity, availability, and needs of the United States, which shall include, to the extent data are available—

(1)

the capacity of acute residential or inpatient detoxification programs;

(2)

the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation programs;

(3)

the capacity of demographic specific residential or inpatient treatment programs, such as those designed for pregnant women or adolescents;

(4)

geographical differences of the availability of residential and outpatient treatment and recovery options for substance use disorders across the continuum of care;

(5)

the availability of residential and outpatient treatment programs that offer treatment options based on reliable scientific evidence of efficacy for the treatment of substance use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies;

(6)

the number of patients in residential and specialty outpatient treatment services for substance use disorders;

(7)

an assessment of the need for residential and outpatient treatment for substance use disorders across the continuum of care;

(8)

the availability of residential and outpatient treatment programs to American Indians and Alaska Natives through an Indian health program (as defined by section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)); and

(9)

the barriers (including technological barriers) at the Federal, State, and local levels to real-time reporting of de-identified information on drug overdoses and ways to overcome such barriers.

May 10, 2016

Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed